265,978 Shares in DENTSPLY SIRONA Inc. $XRAY Bought by Intech Investment Management LLC

Intech Investment Management LLC bought a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 265,978 shares of the medical instruments supplier’s stock, valued at approximately $3,375,000. Intech Investment Management LLC owned 0.13% of DENTSPLY SIRONA at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA in the first quarter valued at approximately $26,000. Goldman Sachs Group Inc. grew its holdings in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares during the period. Empowered Funds LLC increased its position in shares of DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after buying an additional 41,579 shares in the last quarter. Finally, Focus Partners Wealth raised its stake in DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after buying an additional 9,355 shares during the period. Institutional investors own 95.70% of the company’s stock.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

Insider Buying and Selling

In other news, Director Gregory T. Lucier sold 82,200 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.52% of the stock is owned by company insiders.

DENTSPLY SIRONA Stock Up 15.5%

Shares of DENTSPLY SIRONA stock opened at $14.68 on Monday. The business’s 50 day simple moving average is $12.42 and its 200 day simple moving average is $12.47. DENTSPLY SIRONA Inc. has a 52-week low of $9.85 and a 52-week high of $17.34. The firm has a market cap of $2.93 billion, a PE ratio of -4.89, a P/E/G ratio of 1.19 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. During the same period last year, the company earned $0.26 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts predict that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 4.4%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s payout ratio is presently -21.33%.

Analysts Set New Price Targets

A number of research firms have issued reports on XRAY. Barrington Research reissued an “outperform” rating and issued a $14.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, January 5th. Robert W. Baird boosted their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Stifel Nicolaus set a $13.00 price target on shares of DENTSPLY SIRONA in a research note on Thursday, November 6th. Finally, Zacks Research cut shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $14.00.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.